Breaking News Instant updates and real-time market news.

MRK

Merck

$61.35

-0.95 (-1.52%)

13:23
11/22/16
11/22
13:23
11/22/16
13:23

Merck increases dividend by 1c to 47c per share

Merck announced that the board has increased the company's quarterly dividend to 47c per outstanding share of the company's common stock, up 1c from 46c per outstanding share paid last quarter. Payment will be made on Jan. 9, 2017, to stockholders of record at the close of business on Dec. 15, 2016. "We are making strides toward our overarching goal of bringing forward medicines and vaccines that create value for society and shareholders alike. The dividend increase reflects our confidence in our innovation strategy and our commitment to returning meaningful value to our shareholders," said chairman and CEO Kenneth Frazier.

MRK Merck
$61.35

-0.95 (-1.52%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
10/24/16
RHCO
10/24/16
NO CHANGE
RHCO
Merck Keytruda to have several positive catalysts, says SunTrust
SunTrust analyst John Boris says that several trials of Merck's Keytruda will be stopped early "across multiple tumor types," providing a positive catalyst. Boris says that Keytruda should be approved for 1LNSCLC on or before December 24 and KN-21 chemo combo compendium listing in 1H17. He keeps a $73 price target and Buy rating on Merck.
10/25/16
RHCO
10/25/16
NO CHANGE
RHCO
Merck shares should be bought after early FDA approval, says SunTrust
After Merck announced that the FDA had approved the company's Keytruda treatment for the first-line metastatic non-small cell lung cancer with tumor proportion scores of 50% or higher, SunTrust analyst John Boris says that such patients represent about 30% "of the prevalent first-line population." He adds that the approval was earlier than expected and gives Keytruda an approximately 15 month lead over competing drugs in NSCLC. The analyst thinks that the early approval will enable the company's 2021 revenue to beat expectations by a significant amount, and he recommends buying the stock on the news.

TODAY'S FREE FLY STORIES

ADTN

Adtran

08:41
01/16/18
01/16
08:41
01/16/18
08:41
Upgrade
Adtran rating change  »

Adtran upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

FNSR

Finisar

$22.74

0.48 (2.16%)

08:41
01/16/18
01/16
08:41
01/16/18
08:41
Downgrade
Finisar rating change  »

Finisar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

, AVGO

Broadcom

$264.29

0.79 (0.30%)

08:38
01/16/18
01/16
08:38
01/16/18
08:38
Earnings
Qualcomm 'firmly committed' to FY19 adjusted EPS target of $6.75-$7.50 »

As previously reported,…

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

AVGO

Broadcom

$264.29

0.79 (0.30%)

NXPI

NXP Semiconductors

$119.58

0.33 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

MTN

Vail Resorts

$222.31

3.37 (1.54%)

08:38
01/16/18
01/16
08:38
01/16/18
08:38
Recommendations
Vail Resorts analyst commentary  »

Vail Resorts price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$42.81

-0.01 (-0.02%)

, INTC

Intel

$43.24

-0.17 (-0.39%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Recommendations
Micron, Intel analyst commentary  »

Micron pullback a buying…

MU

Micron

$42.81

-0.01 (-0.02%)

INTC

Intel

$43.24

-0.17 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Mar

ATTU

Attunity

$6.71

-0.061 (-0.90%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Hot Stocks
Attunity wins $1.2M in additional business with Fortune 100 company »

Attunity announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

OTIV

On Track Innovations

$1.37

-0.01 (-0.72%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Hot Stocks
On Track Innovations announces additional order of 10,000 cashless readers »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$39.37

-0.39 (-0.98%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Hot Stocks
Synchrony reports December charge-off rate 4.94% vs. 5.03% last month »

Reports December 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

F

Ford

$13.23

0.07 (0.53%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Periodicals
Ford sees savings in 'every part' of business, FT reports »

Ford will have to make…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

MDXG

MiMedx

$13.86

-0.08 (-0.57%)

08:36
01/16/18
01/16
08:36
01/16/18
08:36
Hot Stocks
MiMedx: First patients enrolled in Phase 3 clinical trial of AmnioFix Injectable »

MiMedx Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

UCTT

Ultra Clean

$23.22

0.47 (2.07%)

08:36
01/16/18
01/16
08:36
01/16/18
08:36
Hot Stocks
Ultra Clean sees Q1 revenue up from Q4 »

The company said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LBCC

Long Blockchain Corp.

$5.02

-0.48 (-8.73%)

08:35
01/16/18
01/16
08:35
01/16/18
08:35
Hot Stocks
Breaking Hot Stocks news story on Long Blockchain Corp. »

Long Blockchain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRAY

Cray

08:35
01/16/18
01/16
08:35
01/16/18
08:35
Earnings
Cray sees FY17 revenue about $390M, consensus $399.96M »

Cray announced selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LNG

Cheniere Energy

$54.73

0.29 (0.53%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Hot Stocks
Cheniere Energy, Trafigura sign 15-year LNG sale and purchase agreement »

Cheniere Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

UCTT

Ultra Clean

$23.22

0.47 (2.07%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Earnings
Ultra Clean reaffirms Q4 revenue view $240.0M-$250M, consensus $244.32M »

Sees Q4 operating margins…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

PX

Praxair

$164.15

0.34 (0.21%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Hot Stocks
Praxair expands hydrogen supply to Motiva Port Arthur, Texas refinery »

Praxair, Inc. has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CNCE

Concert Pharmaceuticals

$20.15

-7.53 (-27.20%)

, INCY

Incyte

$94.07

1.01 (1.09%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Downgrade
Concert Pharmaceuticals, Incyte rating change  »

Concert Pharmaceuticals…

CNCE

Concert Pharmaceuticals

$20.15

-7.53 (-27.20%)

INCY

Incyte

$94.07

1.01 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MGM

MGM Resorts

$35.03

-0.08 (-0.23%)

, LVS

Las Vegas Sands

$71.02

0.39 (0.55%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Recommendations
MGM Resorts, Las Vegas Sands, Wynn Resorts, Melco Resorts & Entertainment analyst commentary  »

Morgan Stanley raises…

MGM

MGM Resorts

$35.03

-0.08 (-0.23%)

LVS

Las Vegas Sands

$71.02

0.39 (0.55%)

WYNN

Wynn Resorts

$165.54

3.04 (1.87%)

MLCO

Melco Resorts & Entertainment

$27.01

-0.21 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRWD

Ironwood

$15.12

0.02 (0.13%)

, AGN

Allergan

$176.05

-1.07 (-0.60%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Hot Stocks
Ironwood, Allergan announce settlement with Sun Pharma over LINZESS »

Ironwood Pharmaceuticals…

IRWD

Ironwood

$15.12

0.02 (0.13%)

AGN

Allergan

$176.05

-1.07 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 16

    Feb

  • 25

    Mar

YUMC

Yum China

$45.86

2.06 (4.70%)

08:32
01/16/18
01/16
08:32
01/16/18
08:32
Hot Stocks
Yum China sees one-time tax expense of approximately $160M in Q4 »

Yum China Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

IO

ION Geophysical

$21.35

-2.7 (-11.23%)

08:32
01/16/18
01/16
08:32
01/16/18
08:32
Hot Stocks
ION Geophysical announces Supreme Court granted certiorari »

ION Geophysical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIS

OSI Systems

$67.68

0.19 (0.28%)

08:31
01/16/18
01/16
08:31
01/16/18
08:31
Hot Stocks
OSI Systems signs 2-year contract to continue turnkey screening services »

OSI Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

, TSRO

Tesaro

$69.59

-2.07 (-2.89%)

08:31
01/16/18
01/16
08:31
01/16/18
08:31
Recommendations
Heron Therapeutics, Tesaro analyst commentary  »

Tesaro update could drive…

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

TSRO

Tesaro

$69.59

-2.07 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:31
01/16/18
01/16
08:31
01/16/18
08:31
General news
Empire State Mfg Survey General Business Conditions Index data reported »

January Empire State Mfg…

LMOS

Lumos Networks

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Lumos signs multi-year contract with Roanoke Blacksburg Regional Airport »

Lumos Networks signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.